Travere Therapeutics Inc Financials
Travere Therapeutics Inc (TVTX) reported $490.7M in revenue for fiscal year 2025, up 110.5% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
FY2025 shows a sharp operating-leverage turn: revenue scaled over a still-heavy cost base, pushing cash generation back above zero.
Between FY2024 and FY2025, operating cash flow moved from-$237.5M to$37.8M , a bigger shift than the smaller net loss because cash finally started agreeing with reported results. At the same time, financing cash flow swung from$139.4M to-$33.5M , implying the business relied less on fresh capital and more on its own operations to fund itself.
This looks like fixed-cost absorption more than austerity. Revenue reached
The balance sheet is less strained than the income statement alone suggests, but it is still shaped by accumulated losses. Cash rose to
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Travere Therapeutics Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Travere Therapeutics Inc scores 4.84, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($5.9B) relative to total liabilities ($490.4M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Travere Therapeutics Inc passes 6 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.
Travere Therapeutics Inc reported a net loss of $25.5M while generating $37.8M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
Travere Therapeutics Inc reported an operating loss of $62.8M against $10.7M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Travere Therapeutics Inc generated $490.7M in revenue in fiscal year 2025. This represents an increase of 110.5% from the prior year.
Travere Therapeutics Inc's EBITDA was -$2.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 99.3% from the prior year.
Travere Therapeutics Inc reported -$25.5M in net income in fiscal year 2025. This represents an increase of 92.1% from the prior year.
Travere Therapeutics Inc earned -$0.29 per diluted share (EPS) in fiscal year 2025. This represents an increase of 92.9% from the prior year.
Cash & Balance Sheet
Travere Therapeutics Inc held $93.0M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Travere Therapeutics Inc's gross margin was 97.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 1.2 percentage points from the prior year.
Travere Therapeutics Inc's operating margin was -12.8% in fiscal year 2025, reflecting core business profitability. No change is given against fiscal year 2024: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Travere Therapeutics Inc's net profit margin was -5.2% in fiscal year 2025, showing the share of revenue converted to profit. No change is given against fiscal year 2024: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Travere Therapeutics Inc's ROE was -22.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 522.0 percentage points from the prior year.
Capital Allocation
Travere Therapeutics Inc invested $206.0M in research and development in fiscal year 2025. This represents a decrease of 5.3% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
TVTX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $591.3M | $490.7M+110.5% | $233.2M+60.5% | $145.2M+32.7% | $109.5M-17.0% | $131.8M-33.5% | $198.3M+13.1% | $175.3M+6.8% | $164.2M+6.0% | $154.9M+16.0% | $133.6M+33.7% | $99.9M+254.2% | $28.2M | $0 | N/A | $0 |
| Cost of Revenue | $8.3M | $10.3M+33.5% | $7.7M-32.4% | $11.4M+159.0% | $4.4M+15.8% | $3.8M-37.7% | $6.1M+17.0% | $5.2M-5.3% | $5.5M+53.3% | $3.6M-20.8% | $4.6M+108.4% | $2.2M+282.7% | $571K | $0 | N/A | N/A |
| Gross Profit | $583.1M | $480.4M+113.1% | $225.4M+68.5% | $133.8M+27.4% | $105.0M-17.9% | $128.0M-33.4% | $192.2M+13.0% | $170.1M+7.2% | $158.7M+4.9% | $151.3M+17.3% | $129.0M+32.1% | $97.7M+253.6% | $27.6M | $0 | N/A | N/A |
| R&D Expenses | $227.1M | $206.0M-5.3% | $217.5M-11.2% | $245.0M+3166.5% | $7.5M-96.3% | $201.2M+52.7% | $131.8M-6.5% | $141.0M+13.9% | $123.8M+58.3% | $78.2M+10.4% | $70.8M+40.4% | $50.4M+5.5% | $47.8M+574.7% | $7.1M+969.3% | $663K | N/A |
| SG&A Expenses | $390.6M | $337.2M+27.7% | $264.1M-0.5% | $265.5M+34.4% | $197.5M+56.4% | $126.3M-7.0% | $135.8M+5.3% | $129.0M+24.4% | $103.7M+2.3% | $101.3M+10.2% | $91.9M+15.6% | $79.5M+33.4% | $59.6M+237.2% | $17.7M | N/A | $13K |
| Operating Income | -$40.5M | -$62.8M+80.6% | -$323.8M+16.6% | -$388.1M-21.4% | -$319.8M-60.4% | -$199.4M-13.2% | -$176.2M-28.2% | -$137.4M-71.6% | -$80.0M-48.8% | -$53.8M+7.6% | -$58.2M-14.7% | -$50.7M+36.4% | -$79.8M-222.2% | -$24.8M | N/A | N/A |
| Interest Expense | $9.5M | $10.7M-3.9% | $11.2M-1.0% | $11.3M+2.7% | $11.0M-44.2% | $19.7M+3.1% | $19.1M+1.6% | $18.8M+91.6% | $9.8M+121.8% | $4.4M-6.6% | $4.7M-38.5% | $7.7M+4.1% | $7.4M | $0-100.0% | $84K | N/A |
| Income Tax | $605K | $988K+723.3% | $120K-46.2% | $223K-28.8% | $313K-23.5% | $409K+102.1% | -$19.4M-92085.7% | -$21K-102.6% | $811K-40.7% | $1.4M+114.1% | -$9.7M+17.8% | -$11.8M-378.5% | -$2.5M-3336.8% | $76K | N/A | N/A |
| Net Income | -$43.5M | -$25.5M+92.1% | -$321.5M-188.6% | -$111.4M+60.0% | -$278.5M-54.6% | -$180.1M-6.3% | -$169.4M-15.7% | -$146.4M-42.6% | -$102.7M-71.9% | -$59.7M-24.7% | -$47.9M-140.9% | $117.2M+205.7% | -$110.9M-220.4% | -$34.6M | N/A | -$15K |
| EPS (Diluted) | — | -$0.29+92.9% | -$4.08-172.0% | -$1.50+65.7% | -$4.37-45.2% | -$3.01+15.4% | -$3.56-2.9% | -$3.46-36.2% | -$2.54-64.9% | -$1.54-19.4% | -$1.29-140.7% | $3.17+171.6% | -$4.43 | -$2.44 | N/A | N/A |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
TVTX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $605.2M+1.9% | $594.1M-24.7% | $788.9M+17.3% | $672.6M-13.4% | $776.6M+27.9% | $607.4M+0.4% | $604.8M-14.7% | $709.2M+36.3% | $520.3M-0.9% | $525.3M+2.5% | $512.3M+278.1% | $135.5M+560.9% | $20.5M+757.2% | $2.4M | $4K |
| Current Assets | $437.6M+5.0% | $416.7M-32.4% | $616.8M+26.8% | $486.4M-16.5% | $582.8M+42.0% | $410.4M-4.3% | $429.1M-13.4% | $495.7M+52.1% | $325.8M-2.0% | $332.4M+10.1% | $301.9M+708.7% | $37.3M+397.7% | $7.5M+22481.9% | $33K | $4K |
| Cash & Equivalents | $93.0M+58.9% | $58.5M+0.6% | $58.2M-5.7% | $61.7M-62.8% | $165.8M+95.5% | $84.8M+35.8% | $62.4M-39.3% | $102.9M+3.5% | $99.4M+142.4% | $41.0M+8.5% | $37.8M+107.7% | $18.2M+203.6% | $6.0M+54418.2% | $11K | $1K |
| Inventory | $36.2M-13.6% | $41.9M+344.8% | $9.4M+108.0% | $4.5M-38.2% | $7.3M-3.9% | $7.6M+25.1% | $6.1M+8.2% | $5.6M+5.0% | $5.4M+89.3% | $2.8M+11.4% | $2.5M+216.6% | $801K | N/A | N/A | N/A |
| Accounts Receivable | $80.1M+195.5% | $27.1M+28.0% | $21.2M+27.2% | $16.6M+4.6% | $15.9M-0.1% | $15.9M-11.8% | $18.0M+42.5% | $12.7M-8.7% | $13.9M-25.1% | $18.5M+48.6% | $12.5M+56.5% | $8.0M | N/A | N/A | N/A |
| Goodwill | N/A | $800K0.0% | $800K0.0% | $800K-11.1% | $900K0.0% | $900K-3.8% | $936K0.0% | $936K0.0% | $936K0.0% | $936K0.0% | $936K0.0% | $936K | N/A | N/A | N/A |
| Total Liabilities | $490.4M-8.4% | $535.0M-9.0% | $588.1M-6.6% | $629.7M+32.7% | $474.5M+19.8% | $396.2M+3.3% | $383.6M-1.9% | $390.9M+72.0% | $227.2M+4.5% | $217.5M+2.5% | $212.3M+22.9% | $172.7M+330.0% | $40.2M+592.6% | $5.8M | $67K |
| Current Liabilities | $159.9M-20.3% | $200.8M+12.8% | $177.9M+25.1% | $142.2M+14.6% | $124.1M+33.9% | $92.7M-2.9% | $95.4M-8.8% | $104.6M+22.1% | $85.7M+2.9% | $83.3M-4.3% | $87.0M-19.1% | $107.5M+194.1% | $36.6M+530.5% | $5.8M | $67K |
| Total Equity | $114.8M+94.4% | $59.1M-70.6% | $200.8M+368.6% | $42.9M-85.8% | $302.1M+43.0% | $211.2M-4.5% | $221.2M-30.5% | $318.3M+8.6% | $293.1M-4.8% | $307.8M+2.6% | $300.0M+905.3% | -$37.3M-89.4% | -$19.7M-477.1% | -$3.4M | -$63K |
| Retained Earnings | -$1.5B-1.8% | -$1.4B-28.6% | -$1.1B-11.0% | -$1.0B-32.4% | -$766.0M-30.7% | -$585.9M-40.7% | -$416.4M-54.2% | -$270.0M-52.0% | -$177.7M-57.1% | -$113.1M-73.5% | -$65.2M+63.6% | -$179.2M-162.6% | -$68.2M-103.0% | -$33.6M | -$136K |
Not reported in any period shown, so not listed: Long-Term Debt.
TVTX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $92.7M | $37.8M+115.9% | -$237.5M+15.2% | -$280.0M-50.3% | -$186.3M-1159.4% | -$14.8M+65.4% | -$42.7M+26.6% | -$58.2M-133.2% | -$25.0M-437.1% | $7.4M+315.1% | -$3.4M-147.7% | -$1.4M+97.0% | -$45.9M-160.7% | -$17.6M-542.7% | -$2.7M | -$49 |
| Capital Expenditures | N/A | N/A | N/A | $668K+249.7% | $191K-96.3% | $5.1M-24.6% | $6.8M+3370.3% | $195K-73.2% | $727K-18.0% | $887K-37.9% | $1.4M+6390.9% | $22K-96.7% | $663K+466.7% | $117K+372.3% | $25K | N/A |
| Free Cash Flow | N/A | N/A | N/A | -$280.7M-50.5% | -$186.5M-837.4% | -$19.9M+59.8% | -$49.5M+15.2% | -$58.4M-127.4% | -$25.7M-494.2% | $6.5M+233.8% | -$4.9M-245.1% | -$1.4M+97.0% | -$46.5M-162.7% | -$17.7M-541.2% | -$2.8M | N/A |
| Investing Cash Flow | -$203.0M | $27.9M-71.9% | $99.3M+78.1% | $55.8M+271.3% | -$32.6M+76.3% | -$137.6M-124.4% | -$61.3M-408.7% | $19.9M+109.8% | -$203.3M-545.8% | $45.6M+339.7% | $10.4M+112.9% | -$80.6M | N/A | -$5.4M-218.1% | -$1.7M | N/A |
| Financing Cash Flow | $153.1M | -$33.5M-124.0% | $139.4M-36.3% | $218.8M+86.1% | $117.6M-49.3% | $231.7M+81.4% | $127.7M+6248.9% | -$2.1M-100.9% | $231.9M+4158.3% | $5.4M+241.5% | -$3.8M-103.8% | $101.6M+6.6% | $95.3M+228.9% | $29.0M+553.1% | $4.4M | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0 | $0-100.0% | $2.3M+135.6% | $958K | N/A | N/A |
Not reported in any period shown, so not listed: Dividends Paid.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
TVTX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 97.9%+1.2pp | 96.7%+4.6pp | 92.1%-3.8pp | 96.0%-1.1pp | 97.1%+0.2pp | 96.9%-0.1pp | 97.0%+0.4pp | 96.6%-1.0pp | 97.7%+1.1pp | 96.6%-1.2pp | 97.8%-0.2pp | 98.0% | N/A | N/A | N/A |
| Operating Margin | -12.8% | -138.9% | -267.2% | -292.2% | -151.3% | -88.8%-10.5pp | -78.3%-29.6pp | -48.7%-14.0pp | -34.7%+8.9pp | -43.6%+7.2pp | -50.8% | -283.0% | N/A | N/A | N/A |
| Net Margin | -5.2% | -137.9% | -76.7% | -254.4% | -136.6% | -85.4%-1.9pp | -83.5%-21.0pp | -62.5%-24.0pp | -38.6%-2.7pp | -35.9% | 117.4% | -393.4% | N/A | N/A | N/A |
| Return on Equity | -22.3%+522.0pp | -544.3%-488.8pp | -55.5%+594.4pp | -649.9%-590.3pp | -59.6%+20.6pp | -80.2%-14.0pp | -66.2%-33.9pp | -32.3%-11.9pp | -20.4%-4.8pp | -15.6%-54.6pp | 39.1% | N/A | N/A | N/A | N/A |
| Return on Assets | -4.2%+49.9pp | -54.1%-40.0pp | -14.1%+27.3pp | -41.4%-18.2pp | -23.2%+4.7pp | -27.9%-3.7pp | -24.2%-9.7pp | -14.5%-3.0pp | -11.5%-2.4pp | -9.1%-32.0pp | 22.9%+104.8pp | -81.9%+87.0pp | -168.9% | N/A | -379.3% |
| Current Ratio | 2.74+0.7x | 2.08-1.4x | 3.470.0x | 3.42-1.3x | 4.70+0.3x | 4.43-0.1x | 4.50-0.2x | 4.74+0.9x | 3.80-0.2x | 3.99+0.5x | 3.47+3.1x | 0.35+0.1x | 0.21+0.2x | 0.01 | 0.06 |
| Debt-to-Equity | 4.27-4.8x | 9.06+6.1x | 2.93-11.8x | 14.70+13.1x | 1.57-0.3x | 1.88+0.1x | 1.73+0.5x | 1.23+0.5x | 0.78+0.1x | 0.710.0x | 0.71 | N/A | N/A | N/A | N/A |
| FCF Margin | N/A | N/A | -193.3% | -170.4% | -15.1%+9.9pp | -25.0%+8.4pp | -33.3%-17.7pp | -15.6%-19.9pp | 4.2%+7.8pp | -3.6%-2.2pp | -1.4% | -164.9% | N/A | N/A | N/A |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Travere Therapeutics Inc Ranks
Frequently Asked Questions
What is Travere Therapeutics Inc's annual revenue?
Travere Therapeutics Inc (TVTX) reported $490.7M in total revenue for fiscal year 2025. This represents a 110.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Travere Therapeutics Inc's revenue growing?
Travere Therapeutics Inc (TVTX) revenue grew by 110.5% year-over-year, from $233.2M to $490.7M in fiscal year 2025.
Is Travere Therapeutics Inc profitable?
No, Travere Therapeutics Inc (TVTX) reported a net income of -$25.5M in fiscal year 2025, with a net profit margin of -5.2%.
What is Travere Therapeutics Inc's EBITDA?
Travere Therapeutics Inc (TVTX) had EBITDA of -$2.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Travere Therapeutics Inc's gross margin?
Travere Therapeutics Inc (TVTX) had a gross margin of 97.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Travere Therapeutics Inc's operating margin?
Travere Therapeutics Inc (TVTX) had an operating margin of -12.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Travere Therapeutics Inc's net profit margin?
Travere Therapeutics Inc (TVTX) had a net profit margin of -5.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Travere Therapeutics Inc's return on equity (ROE)?
Travere Therapeutics Inc (TVTX) has a return on equity of -22.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Travere Therapeutics Inc's operating cash flow?
Travere Therapeutics Inc (TVTX) generated $37.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Travere Therapeutics Inc's total assets?
Travere Therapeutics Inc (TVTX) had $605.2M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Travere Therapeutics Inc spend on research and development?
Travere Therapeutics Inc (TVTX) invested $206.0M in research and development during fiscal year 2025.
What is Travere Therapeutics Inc's current ratio?
Travere Therapeutics Inc (TVTX) had a current ratio of 2.74 as of fiscal year 2025, which is generally considered healthy.
What is Travere Therapeutics Inc's debt-to-equity ratio?
Travere Therapeutics Inc (TVTX) had a debt-to-equity ratio of 4.27 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Travere Therapeutics Inc's return on assets (ROA)?
Travere Therapeutics Inc (TVTX) had a return on assets of -4.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Travere Therapeutics Inc's Altman Z-Score?
Travere Therapeutics Inc (TVTX) has an Altman Z-Score of 4.84, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Travere Therapeutics Inc's Piotroski F-Score?
Travere Therapeutics Inc (TVTX) has a Piotroski F-Score of 6 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Travere Therapeutics Inc's earnings high quality?
Travere Therapeutics Inc (TVTX) reported a net loss of $25.5M while generating $37.8M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Travere Therapeutics Inc cover its interest payments?
Travere Therapeutics Inc (TVTX) reported an operating loss of $62.8M against $10.7M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Travere Therapeutics Inc?
Travere Therapeutics Inc (TVTX) scores 70 out of 100 on our Financial Health Score, indicating strong standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.